Vaccine Type-, Age- and Past Infection-Dependence of the Humoral Response to SARS-CoV-2 Spike S Protein

Article activity feed

1. Version published to 10.3389/fimmu.2022.809285

   Feb 28, 2022
2. 

   ScreenIT

   Oct 23, 2021

   SciScore for 10.1101/2021.10.14.21264762: (What is this?)

   Please note, not all rigor criteria are appropriate for all manuscripts.

   Table 1: Rigor

   Ethics

   Consent: All participants provided written consent to participate in the study which was performed according to the EU guidelines and following the ethical principles of the Declaration of Helsinki. Field Sample Permit: Serum sample collection was included in the study “ACE2 as a biomarker with utility for identification of high risk population for SARSCoV-2 infection and prognosis of evolution in COVID-19” approved by Autonomous University of Madrid Research Ethics Committee, no.2352. IRB: Serum sample collection was included in the study “ACE2 as a biomarker with utility for identification of high risk population for SARSCoV-2 infection and prognosis of evolution in COVID-19” approved by …

   SciScore for 10.1101/2021.10.14.21264762: (What is this?)

   Please note, not all rigor criteria are appropriate for all manuscripts.

   Table 1: Rigor

   Ethics	Consent: All participants provided written consent to participate in the study which was performed according to the EU guidelines and following the ethical principles of the Declaration of Helsinki. Field Sample Permit: Serum sample collection was included in the study “ACE2 as a biomarker with utility for identification of high risk population for SARSCoV-2 infection and prognosis of evolution in COVID-19” approved by Autonomous University of Madrid Research Ethics Committee, no.2352. IRB: Serum sample collection was included in the study “ACE2 as a biomarker with utility for identification of high risk population for SARSCoV-2 infection and prognosis of evolution in COVID-19” approved by Autonomous University of Madrid Research Ethics Committee, no.2352.
   Sex as a biological variable	not detected.
   Randomization	not detected.
   Blinding	Serum samples were received coded from the providers and the experimentalists were blinded to their nature until all data analysis was finalized.
   Power Analysis	not detected.
   Cell Line Authentication	Contamination: Cells were routinely tested for the absence of mycoplasma.

   Table 2: Resources

   Antibodies
   Sentences	Resources
   Then cells were stained with 50 µl of the following cocktail of antibodies and viability reagent prepared in working buffer: 1:100 of mouse anti-human IgG1-PE (Ref.: 9054-09, Southern Biotech), 1:100 of mouse anti-human IgM-Pacific Blue (Ref.: PB-320-C100, Exbio), 1:50 of goat anti-human IgA-Alexa Fluor 647 (2052-31, Southern Biotech) and 1:50 of 7-AAD Viability Staining Solution (EXBOO26, Exbio).	anti-human IgG1-PE suggested: None anti-human IgM-Pacific Blue ( Ref . suggested: None anti-human IgA-Alexa Fluor 647 ( 2052-31 , Southern Biotech ) suggested: None
   Experimental Models: Cell Lines
   Sentences	Resources
   Cells: The human T-cell line Jurkat clone E6-1 was acquired from ATCC (TIB-152).	Jurkat suggested: None
   Experimental Models: Organisms/Strains
   Sentences	Resources
   SARS-CoV-2 S Jurkat Flow-Cytometry Immunoassay (JFCI) procedure: Jurkat-S-GFP cells were adjusted to 1,2×105 cells per well and plated in 96 well plates.	Jurkat-S-GFP suggested: None
   Recombinant DNA
   Sentences	Resources
   Jurkat-S-GFP were stablished by transduction with the lentiviral vector based on the epHIV-7 plasmid where the human EGFR reporter was substituted by GFP and the full-length Spike S protein of Wuhan-Hu-1 was cloned (Horndler et al., 2021b).	epHIV-7 suggested: None
   Software and Algorithms
   Sentences	Resources
   Data were processed with FlowJo software (BD).	FlowJo suggested: (FlowJo, RRID:SCR_008520)
   Statistics: All data was analyzed using the GraphPad Prism 7 software.	GraphPad Prism suggested: (GraphPad Prism, RRID:SCR_002798)

   ---

   Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).

   ---

   Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

   ---

   Results from TrialIdentifier: No clinical trial numbers were referenced.

   ---

   Results from Barzooka: We did not find any issues relating to the usage of bar graphs.

   ---

   Results from JetFighter: We did not find any issues relating to colormaps.

   ---

   Results from rtransparent:

   • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
   • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
   • No protocol registration statement was detected.

   ---

   Results from scite Reference Check: We found no unreliable references.

   ---

   Read the original source
3. 

   Version published to 10.1101/2021.10.14.21264762 on medRxiv

   Oct 20, 2021